Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Xylem, Inc. (XYL) Price & Performance

10X Genomics IncTrade
Xylem, Inc.Trade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Xylem, Inc. — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Xylem, Inc. trades at $108 (market cap $25.41B). The key difference: Xylem, Inc. is far larger — about 3× 10X Genomics Inc's market cap, and Xylem, Inc. pays a 1.58% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

TXGXYL
Market Cap
$8.55B$25.41B
Sector
HealthIndustrials
52-Week High
$67.29$152.95
52-Week Low
$11.34$105.69
Enterprise Value
$8.08B$27.18B
Dividend Yield
1.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Xylem, Inc.

XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.

Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Xylem, Inc.

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.

Read more on XYL